SBIR · Apr 2021
NIH/HHS Phase I STTR award of $405,552 for an EGFL6 antibody program in platinum-resistant ovarian cancer.
Tradewind translates scientific insight into innovative ways of…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Bay Area biotechnology company developing first-in-class inhibitory antibody therapeutics for aggressive metastatic cancers, especially late-stage ovarian cancer, with a lead program targeting the secreted protein EGFL6.
Primary product
EGFL6-targeting inhibitory antibody therapeutic for ovarian cancer
Founded
2016
Headquarters
MBC BioLabs, 733 Industrial Rd, San Carlos, CA 94070, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Oncology drug discovery / therapeutic antibody development
Offices
MBC BioLabs, 733 Industrial Rd, San Carlos, CA 94070
Open Positions
0 jobs at Tradewind BioScience
No open positions
Check back later for new openings